Renaissance Capital logo

Satsuma Pharmaceuticals Priced, Nasdaq: STSA

Developing a fast-acting dry powder nasal spray for migraines.

Industry: Health Care

Latest Trade: $15.00 0.00 (0.0%)

First Day Return: n/a

Return from IPO: 0.0%

Industry: Health Care

We are a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine. Our product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is specifically designed to deliver the advantages of DHE while overcoming these shortcomings. We have completed a Phase 1 clinical trial in 42 healthy volunteers, in which STS101 demonstrated rapid and sustained DHE plasma concentrations, low pharmacokinetic variability, and a favorable safety and tolerability profile. In July 2019, we initiated our Phase 3 EMERGE efficacy trial of STS101 and expect to report topline data in the second half of 2020.
more less
IPO News for Satsuma Pharmaceuticals
more
IPO Data
IPO File Date 08/16/2019
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.5
Deal Size ($mm) $83
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/12/2019
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.5
Deal Size ($mm) $83
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters South San Francisco, CA
Founded 2016
Employees 11
Website www.satsumarx.com